- Home
- ANAB vs ECPG Comparison
ANAB vs ECPG Comparison
Compare ANAB & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ECPG
- Stock Information
- Founded
- ANAB 2005
- ECPG 1998
- Country
- ANAB United States
- ECPG United States
- Employees
- ANAB N/A
- ECPG N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- ANAB Health Care
- ECPG Finance
- Exchange
- ANAB Nasdaq
- ECPG Nasdaq
- Market Cap
- ANAB 951.1M
- ECPG 905.2M
- IPO Year
- ANAB 2017
- ECPG 1999
- Fundamental
- Price
- ANAB $36.12
- ECPG $42.06
- Analyst Decision
- ANAB Buy
- ECPG Strong Buy
- Analyst Count
- ANAB 12
- ECPG 3
- Target Price
- ANAB $59.30
- ECPG $62.67
- AVG Volume (30 Days)
- ANAB 365.9K
- ECPG 253.4K
- Earning Date
- ANAB 10-31-2025
- ECPG 11-05-2025
- Dividend Yield
- ANAB N/A
- ECPG N/A
- EPS Growth
- ANAB N/A
- ECPG N/A
- EPS
- ANAB N/A
- ECPG N/A
- Revenue
- ANAB $123,164,000.00
- ECPG $1,467,587,000.00
- Revenue This Year
- ANAB $24.36
- ECPG $27.55
- Revenue Next Year
- ANAB N/A
- ECPG $5.84
- P/E Ratio
- ANAB N/A
- ECPG N/A
- Revenue Growth
- ANAB 304.17
- ECPG 15.50
- 52 Week Low
- ANAB $12.21
- ECPG $26.45
- 52 Week High
- ANAB $38.39
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- ANAB 72.97
- ECPG 46.37
- Support Level
- ANAB $33.01
- ECPG $39.95
- Resistance Level
- ANAB $35.58
- ECPG $45.30
- Average True Range (ATR)
- ANAB 1.67
- ECPG 1.58
- MACD
- ANAB -0.05
- ECPG 0.00
- Stochastic Oscillator
- ANAB 68.61
- ECPG 38.18
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.